Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins.
Commencing with the discovery and characterization of bispecific antibodies, numerous investigations have shown that such antibodies are capable of redirecting cellular cytotoxicity. Clinical trials testing diverse strategies, including those targeting CD16-expressing effector cells, have been conducted or are in progress. This manuscript reviews our clinical trials efforts with bispecific antibodies and describes our experience employing multi-functional binding proteins containing tumor-targeting antibody Fab fragments linked to bacterial superantigens, such as staphylococcal enterotoxin A.
Weiner
L M
LM
Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA. lm_weiner@fccc.edu
Alpaugh
R K
RK
von Mehren
M
M
D018033:Antibodies, Bispecific / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology / Q000627:therapeutic use; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D017452:Receptors, IgG / Q000276:immunology*; D018089:Superantigens / Q000276:immunology / Q000627:therapeutic use*
D018033:Antibodies, Bispecific; D007074:Immunoglobulin G; D018719:Erb-b2 Receptor Tyrosine Kinases; D017452:Receptors, IgG; D018089:Superantigens